U.K.'s Owlstone wins $7M for cancer-detecting breathalyzer

Owlstone Medical has raised £4.9 million ($7 million) to fund the ongoing clinical trials of its diagnostic breathalyzer for lung and colon cancers.

While the funding will go toward testing the device in cancer indications, Owlstone is developing the breathalyzer for clinical diagnostic use in inflammatory and infectious diseases as well.

To find out more, please click here.